2779498-79-0
Chemical Structure
Mindeudesivir hydrobromide
Synonym(s): VV116; GS-621763-d1 hydrobromide
- CAS No.: 2779498-79-0
- Formula:C24H31DBrN5O7
- Molecular Weight:583.45
IUPAC Name: (S)-2-methyl-3-(m-tolyl)propanoic acid
InChIKey: HVRWXEFYGBTUNI-FTPFRNFUSA-N
SMILES: N#C[C@](O[C@@H]1COC(C(C)C)=O)(C2=CC([2H])=C3N2N=CN=C3N)[C@@H]([C@@H]1OC(C(C)C)=O)OC(C(C)C)=O.Br
Biological Activity: Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mindeudesivir hydrobromide | 98.16% | Mindeudesivir (JT001; VV116; GS-621763-d1) hydrobromide is a deuterated version of Remdesivir (HY-104077), a highly orally active nucleoside antiviral against SARS-CoV-2 and respiratory syncytial virus (RSV). Mindeudesivir hydrobromide retains the antiviral activity of Remdesivir against COVID-19, and is the first domestically produced deuterium targeting the COVID-19. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mindeudesivir | 98.20% | GS-621763-d1 is the deuterium labeled GS-621763 (HY-145119). GS-621763, an orally bioavailable proagent of GS-441524, shows antiviral activity against SARS-CoV-2 pathogenesis in mice. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GS-621763 | 99.72% | GS-621763 is an orally available precursor to GS-441524 that exhibits anti-SARS-CoV-2 viral activity in mice. GS-621763 reduces viral load to undetectable levels in ferrets infected with SARS-CoV-2. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zhang R, et al. Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse model. Signal Transduct Target Ther. 2022;7(1):123. Published 2022 Apr 16. [Content Brief]
- [2]. Qian HJ, et al. Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects [published online ahead of print, 2022 Mar 16]. Acta Pharmacol Sin. 2022;1-9. [Content Brief]
